

Appl. No. 10/788,478  
Amdt. dated December 29, 2005  
Reply to Office action of July 29, 2005

**Listing of Claims:**

1. (currently amended) A method for reducing symptoms related to stroke, said therapy comprising the administration of a therapeutically effective amount of at least two compounds selected from the group consisting of an inhibitor of microglial activation, an antiglutaminergic antiglutaminergic agent and a voltage gated calcium channel blocker to a patient suffering from said stroke.
2. (original) The method of claim 1, wherein said inhibitor of microglial activation is minocycline.
3. (original) The method of claim 1, wherein said antiglutaminergic agent is Riluzole.
4. (original) The method of claim 1, wherein said voltage gated calcium channel blocker is Nimodipine.
5. (original) The method of claim 1, wherein said compounds are administered simultaneously.
6. (original) The method of claim 1, wherein said compounds are administered consecutively.
7. (currently amended) A composition for reducing symptoms related to stroke, comprising a therapeutically effective amount of at least two compounds selected from the group consisting of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker in association with a pharmaceutically acceptable carrier.

Appl. No. 10/788,478  
Amdt. dated December 29, 2005  
Reply to Office action of July 29, 2005

8. (original) The composition of claim 7, wherein said inhibitor of microglial activation is minocycline.

9. (original) The composition of claim 7, wherein said antiglutaminergic agent is Riluzole.

10. (original) The composition of claim 7, wherein said voltage gated calcium channel blocker is Nimodipine.